The treatment of chronic insomnia: Drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation unit Meeting Sympoium

Sleep Medicine Reviews

Volumn 8, Issue 1, 2004, Pages 7-17

  Mendelson, Wallace B ^a,b   Roth, Thomas ^a,c   Cassella, James ^a,d   Roehrs, Timothy ^a,e,f   Walsh, James K ^a,g,h   Woods, James H ^a,i   Buysse, Daniel J ^a   Meyer, Roger E ^a  

^a Sleep Disorder Center ^*  (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d NEUROGEN CORPORATION   (United States)

^e HENRY FORD HOSPITAL   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g St Luke's Hospital   (United States)

^h SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Benzodiazepines; Dependence; Hypnotics; Insomnia; Tolerance

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CHLORPHENIRAMINE; DIPHENHYDRAMINE; FEXOFENADINE; FLUNITRAZEPAM; LORATADINE; LORMETAZEPAM; NITRAZEPAM; TEMAZEPAM; TERFENADINE; TRAZODONE; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ANTEROGRADE AMNESIA; ATAXIA; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABUSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; FALLING; HEALTH CARE UTILIZATION; HEART ATRIUM ARRHYTHMIA; HEART DISEASE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPNOSIS; INSOMNIA; MAJOR DEPRESSION; PRIAPISM; RESPIRATION DEPRESSION; SIDE EFFECT; SLEEP;

EID: 1542329142     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1087-0792(03)00042-X     Document Type: Conference Paper

References (50)

1. Consensus conference, Drugs and insomnia. The use of medications to promote sleep. JAMA 1984; 251: 2410-2414.
2. McKernan RM, Whiting P. Which GABA-A receptor subtypes really occur in the brain? Trends Neurosci 1996; 19: 139-143.
3. Rudolph U, Crestani F, Benke D et al. Benzodiazepine actions mediated by specific GABA-A areceptor subtypes. Nature 1999; 401: 796-800.
4. Gallup Organization, Sleep in America. Princeton, NJ: The Gallup Organization 1991.
5. Gallup Organization, Sleep in America: 1995. Princeton, NJ: The Gallup Organization 1995.
6. Kim K, Uchiyama M, Okawa M, Liu X, Ogihara R. An epidemiological study of insomnia among the Japanese general population. Sleep 2000; 23: 41-47.
7. Ohayon MM, Caulet M, Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep 1997; 20: 715-723.
8. Ohayon MM, Partinen M. Insomnia and global sleep dissatisfaction in Finland. J Sleep Res 2002; 11: 339-346.
9. Leger D, Guilleminault C, Dreyfus JP, Delahaye C, Paillard M. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res 2000; 9: 35-42.
10. Kuppermann M, Lubeck DP, Mazonson PD et al. Sleep problems and their correlates in a working population. JGIM 1995; 10: 25-32.
11. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiat 1998; 154: 1417-1423.
12. Ford DE, Kamerow DW. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA 1989; 262: 1479-1484.
13. Weissman MM, Greenwald S, Nino-Murcia G, William DC. The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hospital Psychiat 1997; 19: 245-250.
14. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiat 1991; 52(Suppl.): 16-23.
15. Schweitzer PK, Walsh JK. Ten year trends in the pharmacologic treatment of insomnia. Sleep 1998; 21: 247.
16. Roehrs T, Roth T. Sleep, Sleepiness, sleep disorders and alcohol use and abuse. Sleep Med Rev 2001; 5: 287-297.
17. Johnson EO, Roehrs T, Roth T, Breslau N. Epidemiology of alcohol and medication as aids to sleep in early adulthood. Sleep 1998; 21: 178-186.
18. Walsh JK, Erman M, Erwin CW, Jamieson A, Mahowald M, Aregenstein Q, Scharf M, Tigel P, Vogel G, Ware CJ. Subjective hypnotic efficacy of Trazodone and Zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol 1998; 13: 191-198.
19. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, Semler B, Decker K, Parapatics S, Tschida U, Winkler A, Saletu B. Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls. Neuropsychobiology 2001; 44: 139-149.
20. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, Gruber B, Mandl M, Strobl R, Gollner D, Prause W, Saletu B. Insomnia in depression: differences in objective and subjective steep and awakening quality to normal controls. Prog Neuropsychopharmacol Biol Psychiat 2002; 26: 249-260.
21. Aronson MD, Hafez H. A case of trazodone-induced ventricular tachycardia. J Clin Psychol 1986; 47: 388-389.
22. Rausch JL, Pavlinac DM, Newman PE. Complete heart block following a single dose of trazodone. Am J Psychiat 1984; 141: 1472-1473.
23. Janowsky D, Curtis G, Zisook S, Kuhn R, Resovsky R. Ventricular arrythmias possibly aggravated by trazodone. Am J Psychiat 1983; 140: 796-797.
24. Zalma A, von Moltke LL, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiat 2000; 47: 655-661.
25. Margolese H, Chouinard G. Serotonin syndrome from addition of low-dose trazodone to nefazodone. Am J Psychiat 2000; 157: 1022-1022.
26. Borbely AA, Youmbi-Balderer G. Effect of diphenhydramine on subjective sleep parameters and on motor activity during bedtime. J Clin Pharmacol 1988; 26: 392-396.
27. Kudo Y, Kurihara M. Clinical evaluation of diphenhydramine hydrochloride for the treatment of insomnia in psychiatric patients: a double-blind study. J Clin Pharmacol 1990; 30: 1041-1048.
28. Roth T, Roehrs T, Koshorek G, Sicklesteel BA, Zorick F. Sedative effects of antihistamines. J Allergy Clin Immunol 1987; 80: 94-98.
29. Schweitzer PK, Muehlbach MJ, Walsh JK. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol 1994; 94: 716-724.
30. Hamelin BA, Bouayad A, Methot J et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 2000; 67: 466-477.
31. Ohayon M. Epidemiological study of insomnia in the general population. Sleep 1996; 19(3): S7-S15.
32. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Metaanalysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000; 162: 225-233.
33. Tonne U, Hiltunen AJ, Vikander B, Engelbrektsson K, Bergman H, Bergman I, Leifman H, Borg S. Neuropsychological changes during steady-state drug use, withdrawal and abstinence in primary benzodiazepine-dependent patients. Acta Psychiat Scand 1995; 91: 299-304.
34. Tata PR, Rottings J, Collins M, Pickering A, Jacobson RR. Lack of cognitive recovery following withdrawal from long-term benzodiazepine use. Psychol Med 1994; 24: 203-213.
35. Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L. Mortality hazard associated with prescription hypnotics. Biol Psychiat 1998; 43: 687-693.
36. Rumble R, Morgan K. Hypnotics sleep and mortality in elderly people. J Am Geriatr Soc 1992; 40: 787-791.
37. Kates A, Kates JD, Bixter EO, Scharf MB. Effectiveness of hypnotic drugs with prolonged use: flurazepam and pentobarbital. Clin Pharmacol Ther 1975; 18: 356-363.
38. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiat 1994; 55: 192-199.
39. Walsh JK, Jamieson A, Schweitzer PK, Scharf MB, Ware JC, Erman M. Intermittent use of zolpidem for the treatment of primary insomnia. Sleep 2000; 23: A86.
40. Oswald I, French C, Adam K, Gilham J. Benzodiazepine hypnotics remain effective for 24 weeks. Br Med J 1982; 284: 860-863.
41. Maarek L. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res 1992; 20: 162-170.
42. Ishigooka J, Sugiyama T, Suzuki M, Kobayashi K, Takeuchi H, Murasaki M. Survival analytic approach to long-term prescription of benzodiazepine hypnotics. Psychiat Clin Neurosci 1998; 52: 541-545.
43. Hajak G, Clarenbach P, Fischer W, Rodenbeck A, Bandelow B. Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiat Clin Neurosci 1998; 248: 148-156.
44. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiat 1994; 151: 1172-1180.
45. Morin CM, Culbert JP, Schwaartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiat 1994; 15: 1172-1180.
46. Nowell PD, Mayumdar S, Buysse DJ, Dew MA, Reynolds CF, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997; 278: 2170-2177.
47. Smith MT, Perlis ML, Park A et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiat 2002; 159: 5-11.
48. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia. JAMA 1999; 281: 991-999.
49. Woods JH. Problems and opportunities in regulation of benzodiazepines. J Clin Pharmacol 2003; 38: 773-782.
50. Rush CR, Baker RW, Wright K. Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers. Psychopharmacology 1997; 131: 9-18.